RPM CD19-mbIL15-CAR-T cells / Alaunos Therap, UT MD Anderson Cancer Center, Eden BioCell - LARVOL DELTA

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=2 | Terminated | Sponsor: Eden BioCell Ltd. | N=24 ➔ 2 | Trial completion date: Oct 2036 ➔ May 2022 | Recruiting ➔ Terminated | Trial primary completion date: Oct 2022 ➔ May 2022; CAR-T manufacturing technology can not meet the dose requirement for clinical patients.

CAR T-Cell Therapy • Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • IFNG • IL10 • IL6 • TNFA

CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - P1; N=4; Terminated; Sponsor: M.D. Anderson Cancer Center; N=24 ➔ 4; Trial completion date: Nov 2021 ➔ May 2021; Recruiting ➔ Terminated; Trial primary completion date: Nov 2021 ➔ May 2021; Study halted prematurely

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Bone Marrow Transplantation • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Transplantation • CD19

Ziopharm Oncology Reports First Quarter 2021 Financial Results and Provides Corporate Updates (GlobeNewswire) - "Anticipate the closure of the CD19 RPM CAR-T Allogeneic Phase I Trial at MD Anderson Cancer Center. The trial closure is expected to occur during the second or third quarter of 2021...Research and development expenses were $13.3 million for the first quarter of 2021, compared to $12.7 million for the first quarter of 2020, primarily reflecting increase in cell therapy program costs offset by a decrease in Controlled IL-12 program costs."

Commercial • New P1 trial • Oncology

RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: Eden BioCell Ltd.

New P1 trial • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Indolent Lymphoma • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD19 • IL10 • IL6

Ziopharm Oncology Announces First Patient Infused in CD19 RPM CAR-T Phase I Clinical Trial Being Conducted by Joint Venture Partner Eden BioCell (GlobeNewswire) - “Ziopharm Oncology, Inc…announced today that in March, the first patient was infused in the CD19-Specific Rapid Personalized Manufacturing (‘RPM’) CAR-T Phase I Trial, being conducted by Eden BioCell, its joint venture with TriArm Therapeutics. The patient was treated at National Taiwan University Hospital under the direction of lead investigator, Dr. Shang-Ju Wu...The Company and Eden BioCell will provide updates regarding the experimental treatment and other patient data in the second half of the year at appropriate venue(s), including scientific conferences, publications and / or bespoke events that the Company may convene...Up to 24 patients will be enrolled in this trial.”

P1 data • Trial status • Hematological Malignancies • Oncology

Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update - "The Company’s joint venture partner, Eden BioCell, has commenced filing of an IND for a clinical trial in Taiwan to assess patient-derived (autologous) CD19-specific membrane bound IL-15 (mbIL15) CAR-T cells, produced using our Rapid Personalized Manufacturing (RPM) platform. The team expects the filing to be complete before year end, as planned."

IND • Hematological Malignancies • Oncology

Ziopharm Oncology Reports Third Quarter 2020 Financial Results and Provides Corporate Update (GlobeNewswire) - "Ziopharm CAR-T Study...Up to 24 patients with CD19⁺ leukemias and lymphomas who have relapsed after allogeneic bone marrow transplantation will be enrolled in this investigator-initiated trial (NCT03579888)."

Enrollment status • Hematological Malignancies • Leukemia • Lymphoma • Oncology

CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - P1; N=24; Recruiting; Sponsor: M.D. Anderson Cancer Center; Not yet recruiting ➔ Recruiting

Enrollment open • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukaemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Transplantation • CD19

CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - P1; N=24; Not yet recruiting; Sponsor: M.D. Anderson Cancer Center; N=12 ➔ 24

Enrollment change • Acute Lymphocytic Leukemia • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Gastrointestinal Cancer • Hematological Disorders • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Small Lymphocytic Lymphoma • Transplantation

CD19-Specific T Cells Post AlloSCT (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: M.D. Anderson Cancer Center; N=12 ➔ 0; Not yet recruiting ➔ Withdrawn

Clinical • Enrollment change • Trial withdrawal